FindTrial
Sign In

A study to evaluate the Bio-enhancing activity of Siddha drug Thirikaduku Chooranam along with Anti- Tuberculosis drugs among the Pulmonary Tuberculosis patients.

A simple randomized Cross-Over study to evaluate the Bio-enhancing activity of Siddha drug Thirikaduku Chooranam on the First line Anti- Tuberculosis drugs among the Category-1 Pulmonary Tuberculosis patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031206
Enrollment
6
Registered
2021-02-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders

Interventions

Intervention1: Thirikatuku Chooranam: 2 gm, Twice Daily for 28 days. Control Intervention1: DOTS FIRST LINE TREATMENT combination of 4 drugs Isoniazid: 10-15 mg/kg for 28 days Control Intervention2:

Sponsors

The Director General
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients under DOTS ( Anti- Tuberculosis) Therapy Category 1 for new smear positive patients with pulmonary TB.

Exclusion criteria

Exclusion criteria: h/o Throat cancer h/o Influenza h/o Pneumonia h/o Bronchitis h/o COPD h/o Patients under treatment for any disease other than PT. Pregnant and Lactating mothers h/o HIV positive and AIDS. Other than Category 1 pulmonary TB. If the participant developed with any ADR after taking the standard or Trial drug.

Design outcomes

Primary

MeasureTime frame
Assessing the Bio-enhancing activity of the trial drug by HPLC method in the First line Anti- Tuberculosis drugs among the Category-1 Pulmonary Tuberculosis patients.Timepoint: 35 days—

Secondary

MeasureTime frame
Assessing the bio- availability of the First line Anti- Tuberculosis drugs on integration with Thirikaduku chooranam among the Category-1 Pulmonary Tuberculosis patients through HPLC method.Timepoint: 35 days—

Countries

India

Contacts

Public ContactDr K Nandhagopal

Siddha Clinical Research Unit.

drnandhagopalsiddha@gmail.com8281417248

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026